stoxline Quote Chart Rank Option Currency Glossary
  
Larimar Therapeutics, Inc. (LRMR)
3.34  0.07 (2.14%)    02-14 16:00
Open: 3.31
High: 3.46
Volume: 329,433
  
Pre. Close: 3.27
Low: 3.3
Market Cap: 213(M)
Technical analysis
2025-02-14 4:49:34 PM
Short term     
Mid term     
Targets 6-month :  4.42 1-year :  4.95
Resists First :  3.78 Second :  4.23
Pivot price 3.52
Supports First :  3.05 Second :  2.54
MAs MA(5) :  3.27 MA(20) :  3.52
MA(100) :  5.65 MA(250) :  7.23
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  18.6 D(3) :  12.2
RSI RSI(14): 40.6
52-week High :  13.06 Low :  3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LRMR ] has closed above bottom band by 29.8%. Bollinger Bands are 53.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.47 - 3.48 3.48 - 3.49
Low: 3.27 - 3.28 3.28 - 3.3
Close: 3.32 - 3.34 3.34 - 3.37
Company Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Headline News

Wed, 12 Feb 2025
Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St

Tue, 04 Feb 2025
Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat

Wed, 29 Jan 2025
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com

Wed, 29 Jan 2025
Truist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy Recommendation - Nasdaq

Thu, 23 Jan 2025
Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire

Wed, 08 Jan 2025
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 64 (M)
Shares Float 32 (M)
Held by Insiders 1.7 (%)
Held by Institutions 108 (%)
Shares Short 5,240 (K)
Shares Short P.Month 4,470 (K)
Stock Financials
EPS -1.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.1
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -28.6 %
Return on Equity (ttm) -44.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.16
Qtrly Earnings Growth 0 %
Operating Cash Flow -58 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -2.91
PEG Ratio 0
Price to Book value 1.07
Price to Sales 0
Price to Cash Flow -3.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android